Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2 / Safety and efficacy of Vildagliptin in real life Chilean diabetic patients
Rev. méd. Chile
;
143(1): 63-68, ene. 2015. graf, tab
Article
in Spanish
| LILACS
| ID: lil-742552
ABSTRACT
Background:
Vildagliptin is a dipeptidyl peptidase IV inhibitor (DPP4i). Its efficacy and safety of DPP4i in Chilean real life type 2 diabetic (T2D) patients is not well known.Aim:
To assess the safety profile and effectiveness of 12 weeks of treatment with Vildagliptin for glycemic control in T2D Chilean patients with a poor glycemic control. Patients andMethods:
Retrospective assessment of the effects of Vildagliptin treatment during 12 weeks in 103 T2D patients aged 29 to 92 years (47% males). The main outcomes were changes in glycosylated hemoglobin and the occurrence of adverse effects.Results:
After 12 weeks of Vildagliptin use, glycosylated hemoglobin decreased from 8.3 ± 1.4 to 7.2 ± 1.1% (p < 0.01). Fasting plasma glucose and the number of hypoglycemic events also decreased significantly. No significant weight change was observed. The treatment had good compliance, tolerance and patient satisfaction.Conclusions:
Vildagliptin treatment reduced glycosylated hemoglobin by 1.1% and was well tolerated in this group of diabetic patients.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Saccharomyces cerevisiae
/
Telomerase
/
Saccharomyces cerevisiae Proteins
Country/Region as subject:
South America
/
Chile
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2015
Type:
Article
Affiliation country:
Chile
Institution/Affiliation country:
Hospital del Salvador/CL
Similar
MEDLINE
...
LILACS
LIS